the National Pregnancy Registry for Atypical Antipsychotics was created in order to evaluate the safety of atypical antipsychotic medications taken by women during pregnancy. Since its inception, we have enrolled over 3000 women in the registry, and we have been able to publish data on the reproductive safety of aripiprazole (Abilify), olanzapine (Zyprexa) and queitiine (Seroquels). Now we have some preliminary data on the use of lurasidone (Latuda) during pregnancy.
The National Pregnancy Registry for Atypical Antipsychotics is a prospective pharmacovigilance program in which pregnant women between the ages of 18 and 45 are enrolled and interviewed during pregnancy.